{"id":"https://openalex.org/W2008395492","doi":"https://doi.org/10.1038/clpt.2012.221","title":"Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG-CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism","display_name":"Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG-CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism","alternate_titles":[],"publication_year":2012,"publication_date":"2012-11-07","ids":{"openalex":"https://openalex.org/W2008395492","doi":"https://doi.org/10.1038/clpt.2012.221","mag":"2008395492","pmid":"https://pubmed.ncbi.nlm.nih.gov/23443754"},"language":"en","primary_location":{"id":"doi:10.1038/clpt.2012.221","doi":"https://doi.org/10.1038/clpt.2012.221","is_oa":false,"landing_page_url":"https://doi.org/10.1038/clpt.2012.221","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology &amp; Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2008395492"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050010032","display_name":"Yoshiko Tomita","orcid":"https://orcid.org/0000-0001-5422-792X","observed_orcids":["https://orcid.org/0000-0001-5422-792X"]},"institutions":[{"id":"https://openalex.org/I31591830","display_name":"Sumitomo Dainippon Pharma (Japan)","ror":"https://ror.org/04sapgw72","country_code":"JP","type":"company","lineage":["https://openalex.org/I31591830"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Y Tomita","raw_affiliation_strings":["Clinical Pharmacology, Department of Drug Development, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology, Department of Drug Development, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan","institution_ids":["https://openalex.org/I31591830"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089688722","display_name":"Kazuya Maeda","orcid":"https://orcid.org/0000-0002-9174-5213","observed_orcids":["https://orcid.org/0000-0002-9174-5213"]},"institutions":[{"id":"https://openalex.org/I74801974","display_name":"The University of Tokyo","ror":"https://ror.org/057zh3y96","country_code":"JP","type":"education","lineage":["https://openalex.org/I74801974"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"K Maeda","raw_affiliation_strings":["Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan","institution_ids":["https://openalex.org/I74801974"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5027984186","display_name":"Yuichi Sugiyama","orcid":"https://orcid.org/0000-0002-8452-8835","observed_orcids":["https://orcid.org/0000-0002-8452-8835"]},"institutions":[{"id":"https://openalex.org/I4210110652","display_name":"RIKEN","ror":"https://ror.org/01sjwvz98","country_code":"JP","type":"facility","lineage":["https://openalex.org/I4210110652"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Y Sugiyama","raw_affiliation_strings":["Sugiyama Laboratory, RIKEN Innovation Center, RIKEN Research Cluster for Innovation, Yokohama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sugiyama Laboratory, RIKEN Innovation Center, RIKEN Research Cluster for Innovation, Yokohama, Japan","institution_ids":["https://openalex.org/I4210110652"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5027984186"],"corresponding_institution_ids":["https://openalex.org/I4210110652"],"apc_list":{"value":4410,"currency":"USD","value_usd":4410},"apc_paid":null,"fwci":0.8057,"has_fulltext":false,"cited_by_count":94,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.55015198,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"94","issue":"1","first_page":"37","last_page":"51"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9779999852180481,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9779999852180481,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.019600000232458115,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ethnic-differences","display_name":"ethnic differences","score":0.7850000262260437},{"id":"https://openalex.org/keywords/oatp1b1","display_name":"OATP1B1","score":0.9629999995231628},{"id":"https://openalex.org/keywords/statins","display_name":"statins","score":0.9959999918937683},{"id":"https://openalex.org/keywords/rosuvastatin","display_name":"rosuvastatin","score":0.972000002861023},{"id":"https://openalex.org/keywords/pravastatin","display_name":"pravastatin","score":0.9810000061988831},{"id":"https://openalex.org/keywords/plasma-exposure","display_name":"plasma exposure","score":0.7879999876022339},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7839999794960022},{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.8799999952316284},{"id":"https://openalex.org/keywords/abcg2","display_name":"ABCG2","score":0.8299999833106995},{"id":"https://openalex.org/keywords/organic-anion-transport","display_name":"organic anion transport","score":0.6570000052452087},{"id":"https://openalex.org/keywords/drug-clearance","display_name":"drug clearance","score":0.503000020980835},{"id":"https://openalex.org/keywords/pharmacokinetic-modeling","display_name":"pharmacokinetic modeling","score":0.5419999957084656}],"concepts":[{"id":"https://openalex.org/C2779519902","wikidata":"https://www.wikidata.org/wiki/Q1240093","display_name":"Pravastatin","level":3,"score":0.7898272275924683},{"id":"https://openalex.org/C2780499067","wikidata":"https://www.wikidata.org/wiki/Q415159","display_name":"Rosuvastatin","level":2,"score":0.7764705419540405},{"id":"https://openalex.org/C104950815","wikidata":"https://www.wikidata.org/wiki/Q415607","display_name":"HMG-CoA reductase","level":4,"score":0.6137812733650208},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5961076021194458},{"id":"https://openalex.org/C134651460","wikidata":"https://www.wikidata.org/wiki/Q3100717","display_name":"Reductase","level":3,"score":0.5243763327598572},{"id":"https://openalex.org/C137403100","wikidata":"https://www.wikidata.org/wiki/Q41710","display_name":"Ethnic group","level":2,"score":0.48256009817123413},{"id":"https://openalex.org/C2777320049","wikidata":"https://www.wikidata.org/wiki/Q2989497","display_name":"Hydroxymethylglutaryl-CoA reductase","level":5,"score":0.4515588879585266},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.41489535570144653},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4108525514602661},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.40553173422813416},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4046615958213806},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3360396921634674},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.2641451358795166},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.24345198273658752},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.17812475562095642},{"id":"https://openalex.org/C19165224","wikidata":"https://www.wikidata.org/wiki/Q23404","display_name":"Anthropology","level":1,"score":0.0},{"id":"https://openalex.org/C144024400","wikidata":"https://www.wikidata.org/wiki/Q21201","display_name":"Sociology","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000068718","descriptor_name":"Rosuvastatin Calcium","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000070997","descriptor_name":"ATP Binding Cassette Transporter, Subfamily G, Member 2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001692","descriptor_name":"Biological Transport","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005006","descriptor_name":"Ethnicity","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D005464","descriptor_name":"Fluorobenzenes","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005464","descriptor_name":"Fluorobenzenes","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008099","descriptor_name":"Liver","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009363","descriptor_name":"Neoplasm Proteins","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D014018","descriptor_name":"Tissue Distribution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018528","descriptor_name":"ATP-Binding Cassette Transporters","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D027361","descriptor_name":"Organic Anion Transporters","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D027381","descriptor_name":"Liver-Specific Organic Anion Transporter 1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057911","descriptor_name":"Angiotensin Receptor Antagonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D057911","descriptor_name":"Angiotensin Receptor Antagonists","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1038/clpt.2012.221","doi":"https://doi.org/10.1038/clpt.2012.221","is_oa":false,"landing_page_url":"https://doi.org/10.1038/clpt.2012.221","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology &amp; Therapeutics","raw_type":"journal-article"},{"id":"pmid:23443754","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23443754","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology and therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[{"id":"https://openalex.org/G8705220346","display_name":null,"funder_award_id":"23136101","funder_id":"https://openalex.org/F4320334764","funder_display_name":"Japan Society for the Promotion of Science"},{"id":"https://openalex.org/G8769817138","display_name":"Quantitative prediction of the bioavailability of drugs based on the activities of dexofication enzymes/transporters","funder_award_id":"24689009","funder_id":"https://openalex.org/F4320334764","funder_display_name":"Japan Society for the Promotion of Science"}],"funders":[{"id":"https://openalex.org/F4320334764","display_name":"Japan Society for the Promotion of Science","ror":"https://ror.org/00hhkn466"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":74,"referenced_works":["https://openalex.org/W152943885","https://openalex.org/W1502459074","https://openalex.org/W1604547439","https://openalex.org/W1783939843","https://openalex.org/W1964471078","https://openalex.org/W1967376529","https://openalex.org/W1970559437","https://openalex.org/W1973810935","https://openalex.org/W1975721982","https://openalex.org/W1982755239","https://openalex.org/W1984849493","https://openalex.org/W1985330287","https://openalex.org/W1986885996","https://openalex.org/W1987674565","https://openalex.org/W1996377151","https://openalex.org/W2000484916","https://openalex.org/W2010241890","https://openalex.org/W2014565106","https://openalex.org/W2016562008","https://openalex.org/W2018126221","https://openalex.org/W2019540147","https://openalex.org/W2022507089","https://openalex.org/W2022663382","https://openalex.org/W2024981560","https://openalex.org/W2029925799","https://openalex.org/W2032860698","https://openalex.org/W2033582596","https://openalex.org/W2035975170","https://openalex.org/W2039299577","https://openalex.org/W2039986849","https://openalex.org/W2049731607","https://openalex.org/W2050381784","https://openalex.org/W2052144043","https://openalex.org/W2052209393","https://openalex.org/W2057085148","https://openalex.org/W2057385204","https://openalex.org/W2059863792","https://openalex.org/W2060102878","https://openalex.org/W2063521571","https://openalex.org/W2066328476","https://openalex.org/W2068341110","https://openalex.org/W2074862075","https://openalex.org/W2087015670","https://openalex.org/W2090298231","https://openalex.org/W2091508935","https://openalex.org/W2092621012","https://openalex.org/W2094692338","https://openalex.org/W2096523918","https://openalex.org/W2099891679","https://openalex.org/W2101817712","https://openalex.org/W2113719939","https://openalex.org/W2116905032","https://openalex.org/W2131138924","https://openalex.org/W2139121124","https://openalex.org/W2139681313","https://openalex.org/W2141941946","https://openalex.org/W2143945489","https://openalex.org/W2145788371","https://openalex.org/W2145804243","https://openalex.org/W2149484061","https://openalex.org/W2150060563","https://openalex.org/W2152218609","https://openalex.org/W2152923211","https://openalex.org/W2153754829","https://openalex.org/W2155634239","https://openalex.org/W2156154177","https://openalex.org/W2158305760","https://openalex.org/W2166529261","https://openalex.org/W2167980243","https://openalex.org/W2169453931","https://openalex.org/W2196655928","https://openalex.org/W2414435268","https://openalex.org/W4249964811","https://openalex.org/W4406322481"],"related_works":["https://openalex.org/W2610933624","https://openalex.org/W2948726319","https://openalex.org/W2604472673","https://openalex.org/W2613693335","https://openalex.org/W2627400699","https://openalex.org/W2046057128","https://openalex.org/W1999164183","https://openalex.org/W2469492348","https://openalex.org/W2109051447"],"abstract_inverted_index":{"Because":[0],"the":[1,15,21,33,39,55,95,99,109,112,127,132,154],"plasma":[2,100],"exposure":[3,101],"levels":[4],"of":[5,28,36,41,58,73,102,115,134,138,156],"rosuvastatin":[6,42],"in":[7,13,20,38,54,98,111,131],"Asians":[8,19],"are":[9,76],"generally":[10],"twice":[11],"those":[12],"Caucasians,":[14],"starting":[16],"dose":[17],"for":[18,30,84],"United":[22],"States":[23],"is":[24,140],"set":[25],"to":[26,159],"half":[27],"that":[29,94],"non-Asians.":[31],"However,":[32],"precise":[34],"role":[35],"ethnicity":[37],"clearance":[40],"has":[43],"not":[44],"yet":[45],"been":[46],"clarified.":[47],"This":[48],"review":[49],"focuses":[50],"on":[51],"ethnic":[52,96,129],"variability":[53,75,97,130],"clinical":[56],"pharmacokinetics":[57],"3-hydroxy-3-methylglutaryl":[59],"co-enzyme":[60],"A":[61],"(HMG-CoA)":[62],"reductase":[63],"inhibitors":[64],"(statins)":[65],"and":[66,86,120,126,147],"angiotensin":[67],"II":[68],"receptor":[69],"antagonists.":[70],"The":[71],"mechanisms":[72],"such":[74],"discussed":[77],"quantitatively,":[78],"with":[79,149],"building":[80],"a":[81],"hypothetical":[82],"model":[83,158],"pravastatin,":[85],"validated":[87],"against":[88],"other":[89,160],"statins.":[90],"Our":[91],"analyses":[92],"suggest":[93],"statins":[103],"cannot":[104],"be":[105,143],"explained":[106],"only":[107],"by":[108],"difference":[110],"allele":[113],"frequencies":[114],"organic":[116],"anion-transporting":[117],"polypeptide":[118],"(OATP)1B1":[119],"breast":[121],"cancer":[122],"resistance":[123],"protein":[124],"(BCRP),":[125],"intrinsic":[128],"activity":[133],"OATP1B1":[135,161],"(the":[136],"ratio":[137],"Japanese/Caucasians":[139],"0.584)":[141],"must":[142],"considered.":[144],"Further":[145],"work":[146],"validation":[148],"additional":[150],"data":[151],"will":[152],"clarify":[153],"applicability":[155],"this":[157],"substrates.":[162]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2008395492","counts_by_year":[{"year":2025,"cited_by_count":11},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":14},{"year":2017,"cited_by_count":12},{"year":2016,"cited_by_count":10},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":11},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
